Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Amgen Drug Patent Portfolio

Amgen owns 5 orange book drugs protected by 38 US patents with Otezla Xr having the least patent protection, holding only 5 patents. And Otezla with maximum patent protection, holding 15 patents. and owns 2 purple book drugs protected by 48 US patents Given below is the list of Amgen's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11752129 27 May, 2042
Active
US11969409 27 May, 2042
Active
US12427136 27 May, 2042
Active
US11426404 Dosing of KRAS inhibitor for treatment of cancers 15 Sep, 2040
Active
US11236091 Solid state forms 20 May, 2040
Active
US11827635 Solid state forms 20 May, 2040
Active
US12398133 20 May, 2040
Active
US11744950 Controlled dispense syringe 21 Nov, 2039
Active
US12280056 Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers 18 Nov, 2039
Active
US10519146 KRAS G12C inhibitors and methods of using the same 21 May, 2038
Active
US11098079 Charged depth filtration of antigen-binding proteins 21 Jul, 2037
Active
US11275090 Quantitation of glycan moiety in recombinant glycoproteins 02 Jul, 2037
Active
US10167492 Process for manipulating the level of glycan content of a glycoprotein 01 Dec, 2035
Active
US10822630 Process for manipulating the level of glycan content of a glycoprotein 01 Dec, 2035
Active
US11786866 Process control systems and methods for use with filters and filtration processes 21 Oct, 2035
Active
US10583397 Process control systems and methods for use with filters and filtration processes 28 Jul, 2035
Active
US11384378 Methods for harvesting mammalian cell cultures 04 Jun, 2035
Active
US11427848 Methods for harvesting mammalian cell cultures 04 Jun, 2035
Active
US11077404 Process control systems and methods for use with filters and filtration processes 13 May, 2035
Active
US11130980 Use of monensin to regulate glycosylation of recombinant proteins 05 Apr, 2035
Active
US10106829 Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins 11 Dec, 2034
Active
US10227627 Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins 11 Dec, 2034
Active
US10655156 Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins 11 Dec, 2034
Active
US10907186 Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins 11 Dec, 2034
Active
US10513723 Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins 09 Dec, 2034
Active
US11254963 Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins 09 Dec, 2034
Active
US10092541 Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 Nov, 2034
Active
US9872854 Methods for the treatment of psoriatic arthritis using apremilast 29 Nov, 2034
Active
US11299760 Use of monensin to regulate glycosylation of recombinant proteins 30 Oct, 2034
Active
US10092541 Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 May, 2034
Active
US9872854 Methods for the treatment of psoriatic arthritis using apremilast 29 May, 2034
Active
US10421987 Methods for increasing mannose content of recombinant proteins 29 May, 2034
Active
US10894972 Methods for increasing mannose content of recombinant proteins 29 May, 2034
Active
US11434514 Methods for increasing mannose content of recombinant proteins 29 May, 2034
Active
US11946085 Methods for increasing mannose content of recombinant proteins 29 May, 2034
Active
US9481901 Methods for increasing mannose content of recombinant proteins 29 May, 2034
Active
US11319568 Methods for increasing mannose content of recombinant proteins 10 Mar, 2034
Active
US11459595 Methods for increasing mannose content of recombinant proteins 10 Mar, 2034
Active
US11952605 Methods for increasing mannose content of recombinant proteins 10 Mar, 2034
Active
US9328134 Carbohydrate phosphonate derivatives as modulators of glycosylation 20 Feb, 2034
Active
US11486883 Method for using light scattering in real time to directly monitor and control impurity removal in purification processes 26 Mar, 2033
Active
US11292829 Mammalian cell culture 29 Jun, 2032
Active
US11634476 Mammalian cell culture 29 Jun, 2032
Active
US11685772 Mammalian cell culture 29 Jun, 2032
Active
US9133493 Method for culturing mammalian cells to improve recombinant protein production 20 Apr, 2032
Active
US9388447 Method for culturing mammalian cells to improve recombinant protein production 20 Apr, 2032
Active
US9012178 Dipeptides to enhance yield and viability from cell cultures 05 Aug, 2031
Active
US9320816 Methods of treating cell culture media for use in a bioreactor 14 Nov, 2030
Active
US9856287 Refolding proteins using a chemically controlled redox state 21 Jun, 2030
Active
US8053236 Feed media 19 Jan, 2030
Active
US9228168 Feed media 19 Jan, 2030
Active
US7427638 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Aug, 2028
Active
US7427638 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Feb, 2028
Active
US7867996 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 12 Jun, 2027
Active
US9359435 Methods for modulating mannose content of recombinant proteins 22 May, 2027
Active
US7662930 Polishing steps used in multi-step protein purification processes 24 Apr, 2027
Active
US7888101 Host cells comprising alpha 1,2 mannosidase and culture methods thereof 06 Apr, 2027
Active
US7928205 Methods for refolding of recombinant antibodies 12 Feb, 2027
Active
US7867996 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 12 Dec, 2026
Active
US8247210 Host cells comprising alpha 1,2 mannosidase and culture methods thereof 06 Dec, 2026
Active
US8460896 Host cells and culture methods 06 Dec, 2026
Active
US8680248 Host cells comprising alpha 1,2 mannosidase and culture methods thereof 06 Dec, 2026
Active
US7829595 Rapid dissolution formulation of a calcium receptor-active compound 22 Sep, 2026
Active
US9375405 Rapid dissolution formulation of a calcium receptor-active compound 22 Sep, 2026
Active
US7361649 β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
Active
US7361650 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
Active
US7879842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
Active
US7361649 β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
Active
US7361650 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
Active
US7879842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
Active
US7427659 Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction 15 Mar, 2025
Active
US7364736 Antibodies to OPGL 19 Feb, 2025
Active
US7893101 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof 09 Dec, 2023 Expired
US8058418 Polynucleotides encoding heavy and light chains of antibodies to OPGL 30 Nov, 2023
Active
US6962940 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof 19 Mar, 2023 Expired
US7208516 Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione 19 Mar, 2023 Expired
US7659302 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione 19 Mar, 2023 Expired
US8455536 Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione 19 Mar, 2023 Expired
US8802717 Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione 19 Mar, 2023 Expired
US9018243 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof 19 Mar, 2023 Expired
US9724330 Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione 19 Mar, 2023 Expired
US6020358 Substituted phenethylsulfones and method of reducing TNFα levels 30 Oct, 2018 Expired
US6011068 Calcium receptor-active molecules 08 Mar, 2018 Expired
US6031003 Calcium receptor-active molecules 14 Dec, 2016 Expired
US6313146 Calcium receptor-active molecules 14 Dec, 2016 Expired
US6211244 Calcium receptor-active compounds 23 Oct, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Amgen.

Activity Date Patent Number
Patent litigations
Email Notification
Critical
29 Nov, 2023 US11827635
Recordation of Patent Grant Mailed
Critical
28 Nov, 2023 US11827635
Patent eGrant Notification 28 Nov, 2023 US11827635
Patent Issue Date Used in PTA Calculation
Critical
28 Nov, 2023 US11827635
Recordation of Patent eGrant 28 Nov, 2023 US11827635
Mail Patent eGrant Notification 28 Nov, 2023 US11827635
Payment of Maintenance Fee, 8th Year, Large Entity 21 Nov, 2023 US9375405
Email Notification
Critical
09 Nov, 2023 US11827635
Issue Notification Mailed
Critical
08 Nov, 2023 US11827635
Application Is Considered Ready for Issue
Critical
25 Oct, 2023 US11827635
Dispatch to FDC 25 Oct, 2023 US11827635
Issue Fee Payment Received
Critical
23 Oct, 2023 US11827635
Issue Fee Payment Verified
Critical
23 Oct, 2023 US11827635
Electronic Review
Critical
09 Aug, 2023 US11827635
Email Notification
Critical
09 Aug, 2023 US11827635


Amgen's Drug Patent Litigations

Amgen's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2015, against patent number US7829595. The petitioner , challenged the validity of this patent, with None as the respondent. Click below to track the latest information on how companies are challenging Amgen's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7829595 October, 2015 Institution Denied
(13 Apr, 2016)
Amgen Inc. Complex Innovations, LLC
US7829595 October, 2015 Terminated-Denied
(13 Apr, 2016)


Amgen Drug Patents' Oppositions Filed in EPO

Amgen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 26, 2010, by Ratiopharm Gmbh. This opposition was filed on patent number EP03721414A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17185704A May, 2021 PUREN Pharma GmbH & Co. KG Granted and Under Opposition
EP17185704A Apr, 2021 Aristo Pharma GmbH Granted and Under Opposition
EP17185704A Mar, 2021 TAD Pharma GmbH Granted and Under Opposition
EP18175497A Dec, 2020 Hexal AG Revoked
EP18175495A Dec, 2020 betapharm Arzneimittel GmbH Revoked
EP18175497A Dec, 2020 betapharm Arzneimittel GmbH Revoked
EP17185704A Nov, 2020 betapharm Arzneimittel GmbH Granted and Under Opposition
EP10162667A Mar, 2020 Galenicum Health S.L.U. Revoked
EP10162667A Feb, 2020 Zentiva k.s. Revoked
EP10162667A Feb, 2020 Hexal AG Revoked
EP10162667A Feb, 2020 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Revoked
EP10162667A Feb, 2020 Wuesthoff & Wuesthoff Patentanwälte PartG mbB Revoked
EP18175495A Jan, 2020 BIOGARAN Revoked
EP18175495A Jan, 2020 Accord Healthcare Ltd Revoked
EP18175495A Jan, 2020 Aechter, Bernd Revoked
EP18175495A Jan, 2020 HGF Limited Revoked
EP18175495A Jan, 2020 Glenmark Pharmaceuticals Europe Ltd Revoked
EP17185704A Jan, 2020 Accord Healthcare Ltd Granted and Under Opposition
EP17185704A Jan, 2020 BIOGARAN Granted and Under Opposition
EP17185704A Jan, 2020 HGF Limited Granted and Under Opposition
EP17185704A Jan, 2020 Aechter, Bernd Granted and Under Opposition
EP18175499A Jan, 2020 Accord Healthcare Ltd Revoked
EP18175497A Jan, 2020 MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH Revoked
EP18175497A Jan, 2020 Aechter, Bernd Revoked
EP18175497A Jan, 2020 Accord Healthcare Revoked
EP18175497A Jan, 2020 BIOGARAN Revoked
EP18175499A Jan, 2020 BIOGARAN Revoked
EP18175499A Jan, 2020 HGF Limited Revoked
EP18175499A Jan, 2020 MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH Revoked
EP18175499A Jan, 2020 Aechter, Bernd Revoked
EP18175497A Jan, 2020 Zentiva, k.s. Revoked
EP18175499A Jan, 2020 Hamm&Wittkopp Patentanwälte PartmbB Revoked
EP18175499A Jan, 2020 Gillard, Richard Edward Revoked
EP18175499A Jan, 2020 Glenmark Pharmaceuticals Europe Ltd Revoked
EP17185704A Jan, 2020 Glenmark Pharmaceuticals Europe Ltd Granted and Under Opposition
EP18175497A Jan, 2020 Glenmark Pharmaceuticals Europe Ltd Revoked
EP18175497A Jan, 2020 HGF Limited Revoked
EP18175497A Jan, 2020 Gillard, Richard Edward Revoked
EP17185704A Jan, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP18175497A Jan, 2020 Teva Pharmaceutical Industries Ltd Revoked
EP18175495A Jan, 2020 Teva Pharmaceutical Industries Ltd Revoked
EP18175499A Jan, 2020 Teva Pharmaceutical Industries Ltd Revoked
EP15177140A Oct, 2019 Galenicum Health S.L.U. Granted and Under Opposition
EP15177140A Oct, 2019 KRKA, d.d., Novo mesto Granted and Under Opposition
EP15177140A Oct, 2019 Zentiva k.s. Granted and Under Opposition
EP15177140A Oct, 2019 Cipla Ltd Granted and Under Opposition
EP15177140A Oct, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP15177140A Oct, 2019 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP15177140A Oct, 2019 Dr. Reddy's Laboratories Limited Granted and Under Opposition
EP15177140A Oct, 2019 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Granted and Under Opposition
EP15177140A Oct, 2019 Química Sintética, S.A. Granted and Under Opposition
EP15177140A Oct, 2019 Hexal AG Granted and Under Opposition
EP15177140A Oct, 2019 Generics (UK) Ltd Granted and Under Opposition
EP15177140A Oct, 2019 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP15177140A Oct, 2019 Accord Healthcare Ltd Granted and Under Opposition
EP15177140A Oct, 2019 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Granted and Under Opposition
EP15177140A Oct, 2019 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP10162653A Feb, 2018 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Revoked
EP09003138A Jul, 2017 Accord Healthcare Revoked
EP04781429A Oct, 2013 ZBM PATENTS, S.L. Patent maintained as amended
EP04781429A Oct, 2013 RAFARM S.A. Patent maintained as amended
EP04781429A Oct, 2013 Actavis Group PTC EHF Patent maintained as amended
EP03721414A May, 2010 Ratiopharm GmbH Revoked


Amgen's Family Patents

Amgen drugs have patent protection in a total of 53 countries. It's US patent count contributes only to 16.8% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Amgen Drug List

Given below is the complete list of Amgen's drugs and the patents protecting them.


1. Corlanor

Corlanor is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7867996
(Pediatric)
γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 12 Jun, 2027
(1 year, 5 months from now)
Active
US7867996 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 12 Dec, 2026
(11 months from now)
Active
US7361649
(Pediatric)
β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
(7 months from now)
Active
US7361650
(Pediatric)
γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
(7 months from now)
Active
US7879842
(Pediatric)
Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Aug, 2026
(7 months from now)
Active
US7361649 β-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
(a month from now)
Active
US7361650 γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
(a month from now)
Active
US7879842 Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it 22 Feb, 2026
(a month from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Corlanor's drug page


2. Lumakras

Lumakras is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11426404 Dosing of KRAS inhibitor for treatment of cancers 15 Sep, 2040
(14 years from now)
Active
US11236091 Solid state forms 20 May, 2040
(14 years from now)
Active
US11827635 Solid state forms 20 May, 2040
(14 years from now)
Active
US12398133 20 May, 2040
(14 years from now)
Active
US12280056 Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers 18 Nov, 2039
(13 years from now)
Active
US10519146 KRAS G12C inhibitors and methods of using the same 21 May, 2038
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lumakras's drug page


3. Otezla

Otezla is protected by 15 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10092541
(Pediatric)
Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 Nov, 2034
(8 years from now)
Active
US9872854
(Pediatric)
Methods for the treatment of psoriatic arthritis using apremilast 29 Nov, 2034
(8 years from now)
Active
US10092541 Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 May, 2034
(8 years from now)
Active
US9872854 Methods for the treatment of psoriatic arthritis using apremilast 29 May, 2034
(8 years from now)
Active
US7427638
(Pediatric)
(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Aug, 2028
(2 years from now)
Active
US7427638 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Feb, 2028
(2 years from now)
Active
US7893101 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof 09 Dec, 2023
(2 years ago)
Expired
US6962940 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof 19 Mar, 2023
(2 years ago)
Expired
US7208516 Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione 19 Mar, 2023
(2 years ago)
Expired
US7659302 Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione 19 Mar, 2023
(2 years ago)
Expired
US8455536 Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione 19 Mar, 2023
(2 years ago)
Expired
US8802717 Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione 19 Mar, 2023
(2 years ago)
Expired
US9018243 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof 19 Mar, 2023
(2 years ago)
Expired
US9724330 Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione 19 Mar, 2023
(2 years ago)
Expired
US6020358 Substituted phenethylsulfones and method of reducing TNFα levels 30 Oct, 2018
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Otezla's drug page


4. Otezla Xr

Otezla Xr is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11752129 27 May, 2042
(16 years from now)
Active
US11969409 27 May, 2042
(16 years from now)
Active
US12427136 27 May, 2042
(16 years from now)
Active
US10092541 Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast 29 May, 2034
(8 years from now)
Active
US7427638 (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof 16 Feb, 2028
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Otezla Xr's drug page


5. Sensipar

Sensipar is protected by 6 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7829595 Rapid dissolution formulation of a calcium receptor-active compound 22 Sep, 2026
(8 months from now)
Active
US9375405 Rapid dissolution formulation of a calcium receptor-active compound 22 Sep, 2026
(8 months from now)
Active
US6011068 Calcium receptor-active molecules 08 Mar, 2018
(7 years ago)
Expired
US6031003 Calcium receptor-active molecules 14 Dec, 2016
(9 years ago)
Expired
US6313146 Calcium receptor-active molecules 14 Dec, 2016
(9 years ago)
Expired
US6211244 Calcium receptor-active compounds 23 Oct, 2015
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sensipar's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Neulasta

Neulasta is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9856287 Refolding proteins using a chemically controlled redox state 21 Jun, 2030
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neulasta's drug page


7. Prolia And Xgeva

Prolia And Xgeva is protected by 47 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11744950 Controlled dispense syringe 21 Nov, 2039
(13 years from now)
Active
US11098079 Charged depth filtration of antigen-binding proteins 21 Jul, 2037
(11 years from now)
Active
US11275090 Quantitation of glycan moiety in recombinant glycoproteins 02 Jul, 2037
(11 years from now)
Active
US10167492 Process for manipulating the level of glycan content of a glycoprotein 01 Dec, 2035
(9 years from now)
Active
US10822630 Process for manipulating the level of glycan content of a glycoprotein 01 Dec, 2035
(9 years from now)
Active
US11786866 Process control systems and methods for use with filters and filtration processes 21 Oct, 2035
(9 years from now)
Active
US10583397 Process control systems and methods for use with filters and filtration processes 28 Jul, 2035
(9 years from now)
Active
US11384378 Methods for harvesting mammalian cell cultures 04 Jun, 2035
(9 years from now)
Active
US11427848 Methods for harvesting mammalian cell cultures 04 Jun, 2035
(9 years from now)
Active
US11077404 Process control systems and methods for use with filters and filtration processes 13 May, 2035
(9 years from now)
Active
US11130980 Use of monensin to regulate glycosylation of recombinant proteins 05 Apr, 2035
(9 years from now)
Active
US10106829 Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins 11 Dec, 2034
(8 years from now)
Active
US10227627 Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins 11 Dec, 2034
(8 years from now)
Active
US10655156 Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins 11 Dec, 2034
(8 years from now)
Active
US10907186 Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins 11 Dec, 2034
(8 years from now)
Active
US10513723 Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins 09 Dec, 2034
(8 years from now)
Active
US11254963 Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins 09 Dec, 2034
(8 years from now)
Active
US11299760 Use of monensin to regulate glycosylation of recombinant proteins 30 Oct, 2034
(8 years from now)
Active
US10421987 Methods for increasing mannose content of recombinant proteins 29 May, 2034
(8 years from now)
Active
US10894972 Methods for increasing mannose content of recombinant proteins 29 May, 2034
(8 years from now)
Active
US11434514 Methods for increasing mannose content of recombinant proteins 29 May, 2034
(8 years from now)
Active
US11946085 Methods for increasing mannose content of recombinant proteins 29 May, 2034
(8 years from now)
Active
US9481901 Methods for increasing mannose content of recombinant proteins 29 May, 2034
(8 years from now)
Active
US11319568 Methods for increasing mannose content of recombinant proteins 10 Mar, 2034
(8 years from now)
Active
US11459595 Methods for increasing mannose content of recombinant proteins 10 Mar, 2034
(8 years from now)
Active
US11952605 Methods for increasing mannose content of recombinant proteins 10 Mar, 2034
(8 years from now)
Active
US9328134 Carbohydrate phosphonate derivatives as modulators of glycosylation 20 Feb, 2034
(8 years from now)
Active
US11486883 Method for using light scattering in real time to directly monitor and control impurity removal in purification processes 26 Mar, 2033
(7 years from now)
Active
US11292829 Mammalian cell culture 29 Jun, 2032
(6 years from now)
Active
US11634476 Mammalian cell culture 29 Jun, 2032
(6 years from now)
Active
US11685772 Mammalian cell culture 29 Jun, 2032
(6 years from now)
Active
US9133493 Method for culturing mammalian cells to improve recombinant protein production 20 Apr, 2032
(6 years from now)
Active
US9388447 Method for culturing mammalian cells to improve recombinant protein production 20 Apr, 2032
(6 years from now)
Active
US9012178 Dipeptides to enhance yield and viability from cell cultures 05 Aug, 2031
(5 years from now)
Active
US9320816 Methods of treating cell culture media for use in a bioreactor 14 Nov, 2030
(4 years from now)
Active
US8053236 Feed media 19 Jan, 2030
(4 years from now)
Active
US9228168 Feed media 19 Jan, 2030
(4 years from now)
Active
US9359435 Methods for modulating mannose content of recombinant proteins 22 May, 2027
(1 year, 4 months from now)
Active
US7662930 Polishing steps used in multi-step protein purification processes 24 Apr, 2027
(1 year, 3 months from now)
Active
US7888101 Host cells comprising alpha 1,2 mannosidase and culture methods thereof 06 Apr, 2027
(1 year, 2 months from now)
Active
US7928205 Methods for refolding of recombinant antibodies 12 Feb, 2027
(1 year, 1 month from now)
Active
US8247210 Host cells comprising alpha 1,2 mannosidase and culture methods thereof 06 Dec, 2026
(10 months from now)
Active
US8460896 Host cells and culture methods 06 Dec, 2026
(10 months from now)
Active
US8680248 Host cells comprising alpha 1,2 mannosidase and culture methods thereof 06 Dec, 2026
(10 months from now)
Active
US7427659 Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction 15 Mar, 2025
(9 months ago)
Expired
US7364736 Antibodies to OPGL 19 Feb, 2025
(10 months ago)
Expired
US8058418 Polynucleotides encoding heavy and light chains of antibodies to OPGL 30 Nov, 2023
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Prolia And Xgeva's drug page


Amgen News

Amgen Acquires Cancer Treatment Company Dark Blue for $840 Million - Bloomberg.com

06 Jan, 2026

5 Major Pharmaceutical Stocks Likely to Excel in 2026 - TradingView

23 Dec, 2025

Novo Nordisk or Amgen: Which Healthcare Investment Is the Better Option?

23 Dec, 2025

Trump poised to reveal major agreements with pharmaceutical companies aimed at reducing medication costs - KATU

19 Dec, 2025

See More